Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
110 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Overview 9 Therapeutics Development 10 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Stage of Development 10 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Therapy Area 11 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Indication 12 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Companies 16 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 21 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30 AstraZeneca Plc 30 AVEO Pharmaceuticals Inc 31 Daiichi Sankyo Company Ltd 32 Etubics Corp 33 F. Hoffmann-La Roche Ltd 34 GamaMabs Pharma SA 35 GlaxoSmithKline Plc 36 Hanmi Pharmaceuticals Co Ltd 37 ImmunoGen Inc 38 Kolltan Pharmaceuticals Inc 39 Merrimack Pharmaceuticals Inc 40 Merus NV 41 Novartis AG 42 Shanghai Fosun Pharmaceutical (Group) Co Ltd 43 Sorrento Therapeutics Inc 44 Symphogen A/S 45 Takis Srl 46 XuanZhu Pharma Co Ltd 47 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles 48 AV-203 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AV-353 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 BA-0702 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 elgemtumab - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ETBX-031 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 FCN-411 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 GSK-2849330 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 H4B-121 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 huHER3-8 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 istiratumab - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 KTN-3379 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 lumretuzumab - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 MCLA-125 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 patritumab - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 pirotinib - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 poziotinib - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 sapitinib - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 seribantumab - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 sirotinib - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Sym-013 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 TK-003 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Vaccine to Target HER1, HER2 and HER3 for Oncology - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Projects 89 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products 93 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Featured News & Press Releases 96 Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016 96 Oct 25, 2016: Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer 96 Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress 97 Aug 26, 2016: CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491) 98 Aug 11, 2016: CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer 98 Jul 06, 2016: FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer 99 Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 100 May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer 102 May 18, 2016: Merrimack to Present Data on Seribantumab at the 2016 American Society of Clinical Oncology Annual Meeting 102 May 18, 2016: Kolltan Pharmaceuticals to Report KTN3379 Clinical Data in an Oral Presentation at the Upcoming 2016 American Society of Clinical Oncology Annual Meeting 103 May 17, 2016: Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series 104 May 02, 2016: AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH 105 Apr 20, 2016: Kolltan Pharmaceuticals Presents Preclinical Data on KTN3379 at the 2016 American Association for Cancer Research Annual Meeting 105 Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting 107 Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor 107 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 109 Disclaimer 110
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Early Stage Products, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Products under Development by Companies, H2 2016 (Contd..2) 19 Products under Development by Companies, H2 2016 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Pipeline by AstraZeneca Plc, H2 2016 30 Pipeline by AVEO Pharmaceuticals Inc, H2 2016 31 Pipeline by Daiichi Sankyo Company Ltd, H2 2016 32 Pipeline by Etubics Corp, H2 2016 33 Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 34 Pipeline by GamaMabs Pharma SA, H2 2016 35 Pipeline by GlaxoSmithKline Plc, H2 2016 36 Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 37 Pipeline by ImmunoGen Inc, H2 2016 38 Pipeline by Kolltan Pharmaceuticals Inc, H2 2016 39 Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 40 Pipeline by Merus NV, H2 2016 41 Pipeline by Novartis AG, H2 2016 42 Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2016 43 Pipeline by Sorrento Therapeutics Inc, H2 2016 44 Pipeline by Symphogen A/S, H2 2016 45 Pipeline by Takis Srl, H2 2016 46 Pipeline by XuanZhu Pharma Co Ltd, H2 2016 47 Dormant Projects, H2 2016 89 Dormant Projects (Contd..1), H2 2016 90 Dormant Projects (Contd..2), H2 2016 91 Dormant Projects (Contd..3), H2 2016 92 Discontinued Products, H2 2016 93 Discontinued Products (Contd..1), H2 2016 94 Discontinued Products (Contd..2), H2 2016 95
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
